Argenica Therapeutics (ASX:AGN) has been granted a new US patent (patent number 12,303,550) entitled 'Neuroprotective Peptides' by the United States Patent Office (USPTO).
The company stated that this patent was filed with the USPTO as a divisional application, following the granting of the parent patent by the USPTO. Argenica said the new US patent extends the scope of its earlier parent patent filing by covering the specific use of its neuroprotective peptides in a method of treating a surgical patient at risk of suffering cerebral ischaemia or stroke.
This protection is especially relevant in high-risk cardiac and vascular operations, such as proximal thoracic-aortic repairs and valve replacements, where peri-operative stroke rates can be up to 10 per cent above baseline. The excess risk is largely driven by emboli. These are the tiny fragments of clot, calcium, or other debris that can enter the bloodstream during surgery, lodge in cerebral vessels, and block blood flow to the brain, resulting in a stroke.
Argenica managing director Dr Liz Dallimore said, “Our new divisional US patent further strengthens Argenica’s already wide-ranging protection for neuroprotective peptides. Because stroke is a significant complication after cardiac and other major surgeries, the patent creates an additional clinical and commercial avenue for our lead candidate, ARG-007, and expands the overall potential of this promising neuroprotective drug.”
